Abbott announced that it partnered with CamDiab and Ypsomed to produce an integrated automated insulin delivery (AID) system.
The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around European countries.
According to a news release, the partnership aims to design the integrated AID system to connect Abbott’s FreeStyle Libre 3 sensor — touted as the world’s smallest and most accurate continuous glucose monitoring sensor (CGM) with readings every minute — to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife YpsoPump.
The companies said that the combination of all devices and platforms in the partnership creates a smart, automated process for insulin delivery based on real-time glucose data. The wearable system will continuously monitor glucose levels and automatically adjust and deliver the proper amount of insulin at the right time.
RELATED: Wallaby acquires German company phenox for $543m
Development is expected to finish by the end of 2022, with commercial availability anticipated thereafter.
“Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders,” SVP of Abbott’s Diabetes Care Business Jared Watkin said in the release. “We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”
Last month, Ypsomed and CamDiab announced a collaboration on managing automated insulin delivery with a mobile app, with plans to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.
“We want to help people with diabetes better manage their glucose through advanced technology,” CamDiab Director Roman Hovorka said. “Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night.”
